Search PubMed⌕ Search

Biomedical subjects

M A Gray

Publications and source records attributed to M A Gray.

At least 91 records · Page 5Linked to original sources

The binding of 5 alpha-pregnane-3,20-dione by cytosol and nuclear preparations of guinea pig uterus.

We compared the binding characteristics of [3H]progesterone and 5 alpha-[3H]pregnanedione in cytosol and nuclear preparations of ovariectomized, estrogen-treated guinea pig uterus. There were similarities as well as differences in binding behavior. [3H]Progesterone and 5 alpha-[3H]pregnanedione were bound in cytosol with approximately the same apparent association constants and concentrations of binding sites. When centrifuged on sucrose gradients in 5 mM phosphate buffer, binding peaks with sedimentation coefficients of 7S were found with both. 5 alpha-[3H]Pregnanedione was bound by uterine nuclei and, like [3H]progesterone, required temperature-activated cytosol of estrogen-stimulated uterus. A series of unlabeled steroids had similar relative abilities to displace both [3H]progesterone and 5 alpha-[3H]pregnanedione from receptor complexes in cytosol or nuclei. When cytosol was incubated with increasing concentrations of [3H]progesterone or 5 alpha-[3H]pregnanedione the amount of 5 alpha-[3H]pregnanedione bound exceeded the amount of [3H]progesterone bound at steroid concentrations above 5 x 10(-9) M. This suggested that 5 alpha-pregnanedione was bound by additional components of the cytosol and the suggestion was strengthened by sucrose gradient analysis. At greater than saturating-steroid concentrations, the partition between 7S and 4 S binding proteins was different. [3H]Progesterone bound to 7S binding proteins in preference to 4S binders, whereas 5 alpha-pregnanedione showed relatively more 4S binding.

Animals↗

Astatine-211 labeling of an antimelanoma antibody and its Fab fragment using N-succinimidyl p-astatobenzoate: comparisons in vivo with the p-[125I]iodobenzoyl conjugate.

Astatine-211 labeling of an antimelanoma antibody, NR-ML-05, and its Fab fragment with N-succinimidyl p-[211At]astatobenzoate (2a) has been described. Preparation of the astatinated intermediate 2a was accomplished by distilling astatine-211 from an irradiated bismuth target directly into a reaction mixture containing an organometallic compound, N-succinimidyl p-(tri-n-butylstannyl)benzoate (1), and an oxidant, N-chlorosuccinimide, in 5% HOAc/MeOH. Trapping of distilled astatine as 2a was found to be efficient, resulting in 70-90% yields based on the amount of astatine-211 in the reaction mixture. The dry distillation technique employed gave recoveries of astatine-211 which ranged from 20% to 75%. Conjugation of 2a to NR-ML-05 and its Fab fragment was accomplished in 40-60% yields. The [211At]astatobenzoyl-conjugated antibodies were found to be stable in vitro when challenged by strong denaturants and nucleophilic reagents. Coinjected dual-labeled studies of the 2a astatinated antibodies and the same antibodies labeled with N-succinimidyl p-[125I]iodobenzoate (2b) in athymic mice bearing the human tumor xenograft A375 Met/Mix demonstrated that both radiolabeled antibodies had equivalent tumor localization. Data from the dual-labeled biodistribution of the intact antibody suggests that the astatine is stably attached. Data from the dual-labeled Fab fragment suggests that a portion of the astatine label is released as astatide, either from the astatinated Fab or from a catabolite.

Animals↗

Osteoporosis medications: what's your source of information?

New drugs for osteoporosis continue to be developed as the drug industry recognizes the increasing elderly population. Methods of treatment for osteoporosis differ according to the cause of the osteoporosis in each individual. To carry out appropriate treatment, nurses need to know the types of osteoporosis and their predisposing factors.

Age Factors↗

NSAIDs revisited.

NSAIDs continue to be an important drug classification for management of various orthopaedic conditions. This column introduces three new drugs and updates the reader on Toradol. Adverse effects and nursing implications are addressed.

Anti-Inflammatory Agents, Non-Steroidal↗